Thermo Fisher Scientific (TMO) Scheduled to Post Earnings on Wednesday

Thermo Fisher Scientific (NYSE:TMO) is set to issue its quarterly earnings data before the market opens on Wednesday, April 24th. Analysts expect the company to announce earnings of $4.71 per share for the quarter. Thermo Fisher Scientific has set its FY 2024 guidance at 20.950-22.000 EPS and its FY24 guidance at $20.95 to $22.00 EPS.Parties that wish to listen to the company’s conference call can do so using this link.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The company had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. Thermo Fisher Scientific’s revenue was down 4.9% on a year-over-year basis. During the same quarter last year, the firm posted $5.40 earnings per share. On average, analysts expect Thermo Fisher Scientific to post $22 EPS for the current fiscal year and $24 EPS for the next fiscal year.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $554.65 on Wednesday. The firm’s 50 day moving average is $571.67 and its two-hundred day moving average is $526.87. Thermo Fisher Scientific has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The company has a market cap of $211.72 billion, a P/E ratio of 35.90, a P/E/G ratio of 2.38 and a beta of 0.80.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were paid a dividend of $0.39 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is 10.10%.

Analyst Ratings Changes

Several brokerages have weighed in on TMO. Raymond James raised their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Royal Bank of Canada lifted their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. TheStreet raised shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. Finally, The Goldman Sachs Group lifted their price objective on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $601.56.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by company insiders.

Institutional Trading of Thermo Fisher Scientific

Large investors have recently modified their holdings of the company. Hobbs Group Advisors LLC bought a new stake in Thermo Fisher Scientific in the 4th quarter valued at $73,000. SageView Advisory Group LLC boosted its holdings in Thermo Fisher Scientific by 11.3% in the 4th quarter. SageView Advisory Group LLC now owns 3,532 shares of the medical research company’s stock valued at $2,003,000 after purchasing an additional 359 shares during the period. Sanibel Captiva Trust Company Inc. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth about $831,000. Oarsman Capital Inc. lifted its holdings in shares of Thermo Fisher Scientific by 63.7% during the 4th quarter. Oarsman Capital Inc. now owns 869 shares of the medical research company’s stock worth $461,000 after acquiring an additional 338 shares during the period. Finally, Harbour Investments Inc. lifted its holdings in shares of Thermo Fisher Scientific by 12.3% during the 4th quarter. Harbour Investments Inc. now owns 3,749 shares of the medical research company’s stock worth $1,990,000 after acquiring an additional 411 shares during the period. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.